Loading…
Loading…
CBDL does not currently pay a dividend.
See price against where its own fundamentals say it should trade — the shaded gap is the discount or premium, across five valuation lenses.
Click below to see what's inside, then upgrade to unlock for CBDL and 80,000+ other tickers.
See exactly how CBDL's revenue becomes profit — a Sankey that traces revenue (and its reported segments) through gross profit, operating expenses, and net profit, with the year-over-year change on every line.
The same diagram the Chart Builder draws, right on the Summary tab. Upgrade to unlock it for CBDL and 80,000+ other tickers.
CBD Life Sciences Inc. specializes in formulating and distributing a broad array of organic items infused with cannabidiol. Their extensive range of natural CBD offerings includes hemp tinctures, topical massage oils, targeted recovery and pain relief balms, dietary aids to support anxiety and restful sleep, various consumable treats, and a dedicated collection of products for animal companions. The company's principal operations are conducted from Scottsdale, Arizona.
The CBD product industry in 2026 is projected to generate tens of billions in revenue globally, most commonly estimated around $12-20 billion, with strong growth momentum. Growth is driven by: Wellness products (oils, gummies, topicals) Medical uses (pain, anxiety, epilepsy) Increasing consumer acceptance and retail availability SCOTTSDALE, AZ / ACCESS Newswire / May 5, 2026 / CBD Life Sciences Inc. (OTCID:CBDL) CBD Life Sciences Inc. is proud to announce our latest product CBD Pouches that are Nicotine Free.
SCOTTSDALE, AZ / ACCESS Newswire / April 22, 2026 / CBD Life Sciences Inc. (OTC:CBDL) CBD Life Sciences Inc. is proud to announce the successful execution of a stock purchase agreement with FBC Holding Inc. Under the terms of this agreement, CBD Life Sciences Inc. has purchased 100% of the issued and outstanding stock of Mushroom Madness Inc. and Formrunner Apparel. This strategic acquisition ensures that both Mushroom Madness Inc. and Formrunner Apparel are now fully wholly owned subsidiaries of CBD Life Sciences Inc. (CBDL).
The CBD product industry in 2026 is projected to generate tens of billions in revenue globally, most commonly estimated around $12-20 billion, with strong growth momentum. Growth is driven by: Wellness products (oils, gummies, topicals) Medical uses (pain, anxiety, epilepsy) Increasing consumer acceptance and retail availability SCOTTSDALE, AZ / ACCESS Newswire / April 21, 2026 / CBD Life Sciences Inc. (OTC:CBDL) CBD Life Sciences Inc. is proud to announce the launch of our New CBD Patches.
The natural, functional mushroom market is experiencing rapid growth, projected to exceed USD 60 billion by 2030, driven by rising demand for immunity-boosting, plant-based, and wellness products. Key trends include the dominance of Reishi, Lion's Mane, and Cordyceps in extracts and dietary supplements, alongside a high preference for locally sourced, fresh gourmet varieties.
With the global functional mushroom market projected to exceed $30+ billion and forecasted to grow at an estimated 9-12% CAGR, this strategic Bronx, New York distribution expansion positions CBDL to capture accelerating consumer demand, drive repeat retail velocity, and unlock scalable, high-margin revenue channels. SCOTTSDALE, ARIZONA / ACCESS Newswire / February 3, 2026 / CBD Life Sciences Inc. (OTC:CBDL), a fast-growing wellness and cannabinoid company focused on premium, trend-driven consumer products, today announced that Smoking Scholars, a well-established dispensary located in the Bronx, New York, has expanded its relationship with the Company to become a major distributor of CBDL's Dubai Mushroom Chocolate - one of the most in-demand functional wellness confections currently gaining traction across dispensary and specialty retail channels.